Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Polatuzumab vedotin + BR in R/R MCL post-BTKi
NCT04913103Phase 2Not yet recruiting
- Sponsor
- Kooperativní lymfomová skupina
- Start
- Sep 2021
- Primary completion
- Aug 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of polatuzumab vedotin in mantle cell lymphoma (MCL), sponsored by Kooperativní lymfomová skupina. Planned start Sep 2021; status: not yet recruiting.
02
Drugs
polatuzumab vedotin
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT04913103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04913103.